Medico Remedies
- Market cap
- ₹ 164 Cr.
- P/E
- 11.7x
- P/B
- 2.25x
- 52-week range
- 18.8 – 56.88
- ROE
- 19%
- ROCE
- 23%
- Dividend yield
- 0%
- Debt / equity
- 0.26
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Medico Remedies Limited is an India-based company, principally engaged in the pharmaceutical business. The Company is involved in the development, manufacture and sale of pharmaceutical and nutraceutical products. It focuses on anti-infective, Beta-Lactams, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, hematinic and other supplements. The Company also manufactures and markets capabilities in other drugs such as non-steroidal anti-inflammatory drugs (NSAIDS), antihistaminic, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream and gel for various therapeutic segments. Its products include Doxycycline Capsules, Zenof-400 (Ofloxacin Tablets 400mg), Azithromycin Tablets, Aciclovir Tablets, Cipta Tablets, Cotrimoxazole Tablets, Tos Syrup, Pediatric Co-Trimozole Oral, Med Reactin (Cyproheptadine), and Medivit Syrup, among others. Its syrups include Medivit Syrup and Ferrovit Syrup.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Medico Remedies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)11.7 against a typical 34.3: cheaper than most peers (1st = cheapest).28th of 220
- Sales growth+81.4% against a typical +15.6% from a year earlier.19th of 197
- Profit growth+38.5% against a typical +18.9% from a year earlier.62nd of 160
- Share price, 3 months−58.5% against a typical −0.5%.200th of 200
- Size₹ 164.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).128th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BBB- to BB by 2 agencies- The agencies don't fully agree: CRISIL says BBB-, Brickwork says BB.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil BBB- | Stable | 4 Jun 2026 |
| Brickwork | BWR BB | Stable | 29 May 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 4 Jun 2026 | Reaffirmed | Crisil BBB- | — | CRISIL | ₹ 42 Cr. | |
| 29 May 2026 | Reaffirmed | BWR BB | — | Brickwork | ₹ 17.55 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 13 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 21 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 12 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 14 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 8 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 8 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 30 | 41 | 31 | 39 | 39 | 41 | 38 | 53 | 59 | 57 | 69 |
| Expenses | 39 | 27 | 37 | 28 | 37 | 36 | 35 | 35 | 50 | 54 | 50 | 66 |
| Operating Profit | 3 | 3 | 5 | 3 | 2 | 3 | 7 | 3 | 3 | 4 | 7 | 3 |
| OPM % | 7.3% | 9.2% | 11.3% | 9.2% | 6.1% | 7.9% | 16.1% | 7.4% | 5.2% | 7.4% | 12.6% | 4.8% |
| Other Income | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 3 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 2 | 4 | 2 | 2 | 4 | 6 | 2 | 3 | 4 | 8 | 3 |
| Tax % | 22.6% | 30.1% | 26.9% | 27.1% | 27.2% | 25.1% | 23.9% | 25.5% | 25.9% | 25.1% | 29.7% | 24.6% |
| Net Profit | 2 | 1 | 3 | 2 | 2 | 3 | 4 | 2 | 3 | 3 | 6 | 3 |
| EPS in Rs | 0.29 | 0.17 | 0.37 | 0.19 | 0.19 | 0.32 | 0.52 | 0.22 | 0.31 | 0.35 | 0.71 | 0.3 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 12%
- 5 Years
- 11%
- 3 Years
- 14%
- TTM
- 50%
- 10 Years
- 28%
- 5 Years
- 38%
- 3 Years
- 22%
- TTM
- 34%
- 10 Years
- —
- 5 Years
- 33%
- 3 Years
- −20%
- TTM
- —
- 10 Years
- 14%
- 5 Years
- 17%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Medico Remedies | ₹ 19.20 | ₹ 164 Cr. | 11.7x | 2.3x | 19% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Haresh Mehta
- Chairman of the Board, Legal Head and Chief Financial Officer
- Vidhi Ankit Shah
- Compliance Officer, Company Secretary
- Harshit Haresh Mehta
- Managing Director, Marketing & Export Head and Executive Director
- Rishit Hareshbhai Mehta
- Production - Technical & Quality Control Head and Whole-time Director
- Maheshkumar Darji
- Additional Executive Director
- Gopal Jha
- Administration Manager
- Priyal Mehta
- Marketing Manager
- Dushant Pandey
- Quality Control Manager
Prices are delayed and for information only. Nothing on this page is investment advice.